Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PROCEPT BioRobotics Corporation - Common Stock (NQ:PRCT)

34.16 +0.13 (+0.40%)
Streaming Delayed Price Updated: 11:23 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PROCEPT BioRobotics Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
2 Robotics Stocks Riding the Sensor and Medical Boom
The robotics infrastructure layer is delivering explosive returns. 
Via The Motley Fool
Is Procept BioRobotics Stock a Buy After Investment Company Chicago Capital Scoops Up Nearly 1 Million Shares?
Is Procept BioRobotics Stock a Buy After Investment Company Chicago Capital Scoops Up Nearly 1 Million Shares? 
Via The Motley Fool
Beyond The Numbers: 4 Analysts Discuss PROCEPT BioRobotics Stock
 
Via Benzinga
PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025
From PROCEPT BioRobotics
Via GlobeNewswire
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Where PROCEPT BioRobotics Stands With Analysts
 
Via Benzinga
Earnings Scheduled For April 24, 2025
 
Via Benzinga
4 Analysts Assess PROCEPT BioRobotics: What You Need To Know
 
Via Benzinga
Assessing PROCEPT BioRobotics: Insights From 4 Financial Analysts
 
Via Benzinga
Procept (PRCT) Q2 Revenue Jumps 48%
Via The Motley Fool
Topics Artificial Intelligence
PROCEPT BioRobotics (PRCT) Earnings Transcript
Via The Motley Fool
Topics World Trade
PROCEPT BioRobotics Corp. (NASDAQ:PRCT) Reports Q2 2025 Revenue Growth but Misses Profitability Targets, Triggering After-Hours Decline
PROCEPT BioRobotics posted strong Q2 2025 revenue growth of 48% YoY but missed profitability estimates, triggering an 8% stock drop. The surgical robotics firm raised full-year guidance but faces... 
Via Chartmill
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
Earnings Scheduled For February 25, 2025
 
Via Benzinga
How Is The Market Feeling About PROCEPT BioRobotics?
 
Via Benzinga
Uncovering Potential: PROCEPT BioRobotics's Earnings Preview
 
Via Benzinga
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
From PROCEPT BioRobotics
Via GlobeNewswire
Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025
From PROCEPT BioRobotics
Via GlobeNewswire
Aquablation® Therapy’s Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas
From PROCEPT BioRobotics
Via GlobeNewswire
WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
Aquablation therapy delivers similar symptom score reduction, superior ejaculatory function preservation, and superior continence preservation to laser enucleation in 80–180 mL prostates in a... 
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® Reports Fourth Quarter and Full Year 2024 Results
From PROCEPT BioRobotics
Via GlobeNewswire
PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference
From PROCEPT BioRobotics
Via GlobeNewswire
Spruce Point Sees Trouble Ahead For Procept BioRobotics
Spruce Point Capital warns of Procept BioRobotics' overstated market potential and growth claims, citing niche product limitations and valuation risks. 
Via Benzinga
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.